Nuvation Bio has reported updated long-term follow-up findings from the Phase II J201 trial assessing safusidenib in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma.

The study (NCT04458272) assessed safusidenib, also known as DS-1001b, in 27 patients to determine confirmed clinical benefit, target lesion reductions, and expected progression-free survival results.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Presented in Philadelphia at the Society for Neuro-Oncology 31st Annual Meeting, the data demonstrated an 81.5% centrally assessed confirmed clinical benefit rate.

Central review established a confirmed objective response rate (ORR) of 51.9%, which comprised 14.8% partial responses in four patients and 37.0% minor responses in 10 patients.

Median time to response reached 14.1 months, while median response duration remained unreached, accompanied by a -27.2% median best per cent reduction in target lesion size.

Earlier reporting showed a 52% response rate and 79% 36-month progression-free survival (PFS), whereas median drug exposure has reached 46.7 months, with ongoing treatment beyond 36 months.

Treatment-emergent adverse events (TEAEs) were mostly low-grade, led by alopecia (59.3%), skin hyperpigmentation (51.9%), arthralgia (55.6%), increased ALT (40.7%), and rash at 37.0%.

Managed through dose modifications, adverse events caused treatment discontinuation in 11.1% of patients, representing three cases, with safusidenib maintaining a manageable profile lacking new safety signals.

Nuvation Bio founder, president and CEO David Hung said: “These compelling long-term data reinforce our confidence in safusidenib’s differentiated profile and potential to deliver sustained disease control.

“As we advance our global pivotal Phase III SIGMA study and expand evaluation into more settings, these results bring us closer to our goal of delivering a transformative medicine across the entire continuum of IDH1-mutant glioma.”

In August 2026, safusidenib received the US Food and Drug Administration’s (FDA) fast track designation (FTD) for treating patients diagnosed with IDH1-mutant glioma.

The therapy will undergo further evaluation in the pivotal Phase III SIGMA trial (NCT05303519), comparing safusidenib against placebo as maintenance therapy in around 300 patients with high-risk IDH1-mutant astrocytoma.